Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results From the Phase 3 PROSERA Trial

Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results From the Phase 3 PROSERA Trial Meeting Abstract

publication date

June 1, 2026

webpage

Web of Science

published in

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE Journal

volume

212